Effectiveness of propagermanium treatment in multiple myeloma patients.

Abstract

Interferon (IFN) is one of several drugs effective in treating multiple myeloma (MM), and propagermanium is an IFN inducer. We report on 10 MM patients who were treated with propagermanium at doses from 10 to 40 mg. Two patients achieved complete remission (CR), two patients achieved partial remission (PR), and the condition of four patients was stable (stable disease, SD). After discontinuation of propagermanium, the status of MM progressed in two patients who were in SD and in two patients who had achieved PR. The administration of propagermanium was restarted in one patient resulting in a decrease in her paraprotein.

• Authors: Yutaka Tsutsumi, Junji Tanaka, Hiroe Kanamori, Mio Musashi, Hiina Minami, Arata Fukushima, Hiroaki Yamato, Nobuyuki Ehira, Takahito Kawamura, Shinji Obara, Nobutaka Ogura, Masahiro Asaka, Masahiro Imamura, Nobuo Masauzi
• Journal: European journal of haematology (Eur J Haematol) Vol. 73 Issue 6 Pg. 397-401 (Dec 2004) ISSN: 0902-4441 [Print] England
• PMID: 15522060 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Interferon Inducers
• Myeloma Proteins
• Organometallic Compounds
• Propionates
• Germanium
• propagermanium

Topics

• Aged
• Aged, 80 and over
• Disease Progression
• Female
• Germanium
• Humans
• Interferon Inducers (therapeutic use)
• Male
• Middle Aged
• Multiple Myeloma (drug therapy)
• Myeloma Proteins (analysis)
• Organometallic Compounds (therapeutic use)
• Propionates
• Remission Induction
• Treatment Outcome